Project Details
Description
First in human, single arm, single center, open-label, proof of concept study to evaluate the safety and tolerability of infusing HSC835 (LFU835-expanded umbilical cord blood hematopoietic stem cells)in patients with hematological malignancies.
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/11 → 11/2/16 |
Funding
- NOVARTIS PHARMACEUTICALS CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.